- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03773302
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
March 29, 2023 updated by: QED Therapeutics, Inc.
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial
Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma.
The purpose of the study is to evaluate the efficacy and safety of the investigational agent oral infigratinib vs standard of care chemotherapy (gemcitabine plus cisplatin) in first-line treatment of participants with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion/rearrangement. Subjects will be randomized 2:1 to receive infigratinib or gemcitabine plus cisplatin.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Camperdown, New South Wales, Australia
- Chris O'Brien Lifehouse Hospital
-
Darlinghurst, New South Wales, Australia
- Blacktown Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia
- Royal Adelaide Hospital
-
-
Victoria
-
Bentleigh East, Victoria, Australia
- Monash Medical Centre
-
Frankston, Victoria, Australia
- Peninsula & South Eastern Haematology and Oncology Group
-
-
Western Australia
-
Subiaco, Western Australia, Australia
- St John of God Hospital Subiaco
-
-
-
-
-
Charleroi, Belgium, 6000
- Grand Hopital de Charleroi
-
Edegem, Belgium, 2650
- Universitair Ziekenhuis Antwerpen
-
-
Brussels
-
Bruxelles, Brussels, Belgium, 1200
- Cliniques Universitaires Saint-Luc
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada
- Cross Cancer Institute
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Ottawa Hospital
-
Toronto, Ontario, Canada
- St. Josephs Health Centre
-
-
Quebec
-
Montréal, Quebec, Canada, H3T 1E2
- Jewish General Hospital
-
-
-
-
-
Beijing, China, 100142
- Beijing Cancer Hospital
-
Beijing, China, 100191
- Peking University Third Hospital
-
Beijing, China, 100033
- Peking University People's Hospital
-
Changsha, China, 410006
- Hunan Cancer Hospital
-
Guangzhou, China, 510080
- Guangzhou First People's Hospital
-
Hubei, China, 430079
- Hubei Cancer Hospital
-
Shenyang, China, 110042
- Liaoning Cancer Hospital & Institute
-
Zhongshan, China, 510060
- The First Affiliated Hospital, Sun Yat-sen University
-
-
-
-
-
Dijon, France, 21079
- Centre Georges-François Leclerc
-
Dijon, France, 21000
- CHRU DIjon
-
Lille, France, 59000
- Hopital Claude Huriez Rue Michel Polonovski (CHRU) Lille
-
Lyon, France, 69437
- Groupement Hospitalier Edouard Herriot
-
Montbéliard, France, 25200
- Hôpital Nord Franche-Comté
-
Nice, France, 06202
- Groupe Hospitalier Archet I Et II
-
Paris, France, 75014
- Hôpital Cochin
-
Paris, France, 75571
- Hopital Saint Antoine
-
Paris, France, 75674
- L'Institut Mutualiste Montsouris
-
-
Val-de-Marne
-
Créteil, Val-de-Marne, France, 94000
- Hôpital Henri Mondor
-
-
-
-
-
Dortmund, Germany, 44137
- Klinikum Dortmund gGmbH
-
Heidelberg, Germany, 69120
- University Clinic Heidelberg
-
-
Baden-Wurttemberg
-
Tübingen, Baden-Wurttemberg, Germany, 72076
- Universitätsklinikum Tübingen
-
-
Bayern
-
München, Bayern, Germany, 81675
- Klinikum rechts der Isar der Technischen Universitat Munchen
-
-
-
-
-
Cremona, Italy, 26100
- Azienda Socio Sanitaria Territoriale di Cremona (ASST)
-
Meldola, Italy, 47014
- Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST
-
Milano, Italy, 20122
- Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico
-
Milano, Italy, 20162
- ASST Grande Ospedale Metropolitano Niguarda
-
Padova, Italy, 35128
- Istituto Oncologico Veneto - I.R.C.C.S.
-
Roma, Italy, 00128
- Policlinico Universitario Campus Biomedico Di Roma
-
-
-
-
-
Pusan, Korea, Republic of
- Pusan National University Hospital
-
Seongnam-si, Korea, Republic of
- Seoul National University Bundang Hospital
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
Seoul, Korea, Republic of, 07061
- SMG - SNU Boramae Medical Center
-
Seoul, Korea, Republic of
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul, Korea, Republic of
- Severance Hospital Yonsei University Health System
-
Suwon-si, Korea, Republic of
- Ajou University Hospital
-
-
-
-
-
Almada, Portugal, 2801-951
- Hospital Garcia de Orta
-
Coimbra, Portugal, 3000-075
- Centro Hospitalar E Universitario de Coimbra EPE
-
Coimbra, Portugal, 3000-075
- Instituto Português de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra EPE
-
Lisboa, Portugal, 1998-018
- Hospital Cuf Descobertas
-
Lisboa, Portugal, 1649-035
- Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria
-
Lisbon, Portugal, 1099-023
- Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.
-
Porto, Portugal, 4200-319
- Centro Hospitalar de São João, E.P.E.
-
Porto, Portugal, 4200-072
- Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
-
Porto, Portugal, 4099-001
- Centro Hospitalar do Porto - Hospital de Santo António
-
-
Lisboa
-
Loures, Lisboa, Portugal, 2674-514
- Hospital Beatriz Angelo
-
-
-
-
-
Rio Piedras, Puerto Rico, 00935
- Hospital Oncologico, Puerto Rico Medical Center
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitario Vall d'Hebron - PPDS
-
Madrid, Spain, 28034
- Hospital Universitario Ramón y Cajal
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
Madrid, Spain, 28007
- Hospital General Universitario Gregorio Marañon
-
Madrid, Spain, 28050
- Hospital Universitario HM Sanchinarro - CIOCC
-
Valencia, Spain, 46026
- Hospital Universitari i Politecnic La Fe de Valencia
-
-
Andalucia
-
Sevilla, Andalucia, Spain, 41009
- Hospital Universitario Virgen Macarena
-
-
Aragon
-
Zaragoza, Aragon, Spain, 50009
- Hospital Universitario Miguel Servet
-
-
Castilla Y Leon
-
Salamanca, Castilla Y Leon, Spain, 37007
- Complejo Asistencial Universitario de Salamanca - Hospital Clínico
-
-
Cataluna
-
Badalona, Cataluna, Spain, 08916
- Hospital Universitario Germans Trias i Pujol
-
Barcelona, Cataluna, Spain, 08907
- Instituto Catalan de Oncologio ICO I'Hospitalet
-
-
-
-
-
Huwei, Taiwan, 632
- National Taiwan University Hospital - YunLin Branch
-
Kaohsiung, Taiwan, 833
- Chang Gung Memorial Hospital - Kaohsiung
-
Taichung City, Taiwan, 40447
- China Medical University Hospital
-
Tainan, Taiwan, 73657
- Chi Mei Hospital, Liouying
-
Taipei, Taiwan
- National Taiwan University Hospital
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taoyuan City, Taiwan, 333
- Chang Gung Memorial Hospital, Linkou
-
-
Tainan
-
Tainan City, Tainan, Taiwan, 704
- National Cheng Kung University Hospital
-
-
-
-
-
Bangkok, Thailand, 10330
- Chulalongkorn University
-
Bangkok, Thailand
- Ramathibodi Hospital Mahidol University
-
Chiang Mai, Thailand, 50200
- Maharaj Nakorn Chiang Mai Chiang Mai University
-
Khon Kaen, Thailand
- Srinagarind Hospital
-
Phitsanulok, Thailand
- Naresuan University
-
-
Songkla
-
Hat Yai, Songkla, Thailand, 90110
- Songklanagarind Hospital, Prince of Songkla University
-
-
-
-
-
London, United Kingdom, SE1 9RT
- Guys Hospital
-
Manchester, United Kingdom, M20 4BX
- The Christie NHS Foundation Trust - PPDS
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
- Nottingham City Hospital
-
-
Surrey
-
Sutton, Surrey, United Kingdom, SM2 5PT
- Royal Marsden Hospital
-
-
Wirral
-
Bebington, Wirral, United Kingdom, CH63 4JY
- The Clatterbridge Cancer Centre NHS Foundation Trust
-
-
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Banner MD Anderson Cancer Center
-
Tucson, Arizona, United States, 85724
- University of Arizona
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Fullerton, California, United States, 92835
- St. Joseph Heritage Healthcare
-
Los Angeles, California, United States, 90095
- University Of California Los Angeles
-
Los Angeles, California, United States, 90033
- USC Norris Cancer Center
-
-
Florida
-
Orlando, Florida, United States, 32806
- UF Health Cancer Center at Orlando Health
-
Orlando, Florida, United States, 32804
- Florida Hospital Medical Group
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- University Medical Center - New Orleans
-
-
Maryland
-
Frederick, Maryland, United States, 21702
- Frederick Regional Healthcare Systems/James M. Stockman Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Barbara Ann Karmanos Cancer Institute - Lawrence and Idell Weisberg Cancer Treatment Center
-
Grand Rapids, Michigan, United States, 49503
- Cancer and Hematology Centers of Western Michigan
-
Royal Oak, Michigan, United States, 48073
- William Beaumont Hospital
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10016
- NYU Langone Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Levine Cancer Institute - Charlotte
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati Medical Center
-
Columbus, Ohio, United States, 43202
- Ohio State University Comprehensive Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29414
- Charleston Oncology
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
Dallas, Texas, United States, 75343
- Parkland Health and Hospital System
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
Houston, Texas, United States, 77096
- Baylor College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or cytologically confirmed unresectable locally advanced or metastatic cholangiocarcinoma. Participants with gallbladder cancer or ampulla of Vater carcinoma are not eligible
- Have written documentation of local laboratory or central laboratory determination of a known or likely activating FGFR2 fusion/rearrangement from a sample collected before randomization
- Have an archival tumor tissue sample available with sufficient tumor content for FGFR2 fusion/rearrangement molecular testing by the central laboratory. However, if an archival tumor tissue sample is not available, or does not meet requirements for central testing a newly obtained (before randomization) tumor biopsy may be submitted instead. If a prestudy written documentation of FGFR2 fusion/rearrangement in tumor tissue is available from the central laboratory, an additional tumor sample does not need to be submitted.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Are able to swallow and retain oral medication
- Are willingness to avoid pregnancy or father children
Exclusion Criteria:
Received treatment with any systemic anti-cancer therapy for unresectable locally advanced or metastatic cholangiocarcinoma, with following exceptions
- Prior neoadjuvant or adjuvant therapy is permitted if completed > 6 months after the last dose of neoadjuvant or adjuvant therapy.
- One cycle of gemcitabine-based chemotherapy for locally advanced or metastatic cholangiocarcinoma is permitted before randomization
- History of a liver transplant
- Received previously or currently is receiving treatment with a mitogen activated protein kinase kinase (MEK) or selective FGFR inhibitor
- Have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral infigratinib (such as, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).
- Current evidence of endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis etc.
- History and/or current evidence of extensive tissue calcification including, but not limited to, the soft tissue, kidneys, intestine, myocardium, vascular system and lung with the exception of calcified lymph nodes, minor pulmonary parenchymal calcifications, and asymptomatic coronary calcification
- Current evidence of corneal or retinal disorder/keratopathy
- Receiving and continued treatment or are planning to receive agents or consuming foods that are known moderate or strong inducers or inhibitors of CYP3A4 and medications which increase serum phosphorus and/or calcium concentration
- Clinically significant or uncontrolled cardiac disease
- Recent (≤ 3 months prior to first dose of study drug) transient ischemic attack or stroke
- Severe hearing loss
- Severe neuropathy
- History of another primary malignancy within 3 years except adequately treated in-situ carcinoma of the cervix or non-melanoma skin cancer or other curatively treated malignancy that is not expected to require treatment
- Pregnant or breastfeeding
- Have known microsatellite instability-high (MSI-H) disease and the decision is made by the treating investigator that an alternative, non-study therapy is warranted according to standard of care.
- Have any known hypersensitivity to gemcitabine, cisplatin, calcium-lowering agents, infigratinib, or their excipients
- Have any contraindication to cisplatin or gemcitabine treatment according to local labeling or standard institutional practice.
- Have taken any Chinese herbal medicine or Chinese patent medicine treatments with anticancer activity within 14 days of the first dose of study drug.
- Have received a live vaccine within 30 days before the first dose of study drug or are planning to receive a live vaccine during participation in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Infigratinib (BGJ398) 125 mg
Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
|
Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
Other Names:
|
Active Comparator: Gemcitabine + Cisplatin
Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib if certain criteria are met.
|
Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle.
Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle.
Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (central imaging assessment)
Time Frame: Approximately 11 months on average
|
Defined as the time from randomization until date of disease progression by blinded independent central imaging assessment (Response Evaluation Criteria in Solid Tumors [RECIST] v. 1.1) or death, whichever occurs first.
|
Approximately 11 months on average
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival in participants treated with infigratinib versus gemcitabine with cisplatin
Time Frame: Approximately 15 months on average
|
Defined as time from date of randomization until death due to any cause
|
Approximately 15 months on average
|
Investigator assessed progression free survival in participants treated with infigratinib compared to gemcitabine and cisplatin
Time Frame: Approximately 10 months on average
|
Defined as the time from randomization until date of disease progression by site investigator (RECIST v1.1) or death, whichever occurs first.
|
Approximately 10 months on average
|
Evaluate the efficacy in participants treated with infigratinib versus gemcitabine with cisplatin by overall response rate (ORR) determined by blinded independent central assessment and the investigator.
Time Frame: Approximately 10 months on average
|
Approximately 10 months on average
|
|
Evaluate the efficacy in participants treated with infigratinib versus gemcitabine with cisplatin by best overall response (BOR) determined by blinded independent central assessment and the investigator.
Time Frame: Approximately 10 months on average
|
Approximately 10 months on average
|
|
Evaluate the efficacy in participants treated with infigratinib versus gemcitabine with cisplatin by duration of response (DOR) determined by blinded independent central assessment and the investigator.
Time Frame: Approximately 10 months on average
|
Approximately 10 months on average
|
|
Evaluate the efficacy in participants treated with infigratinib versus gemcitabine with cisplatin by disease control rate (PR+CR+SD) determined by blinded independent central assessment and the investigator.
Time Frame: Approximately 10 months on average
|
Approximately 10 months on average
|
|
Number of participants with adverse events (AEs) and serious adverse events (SAEs) as a measure of safety and tolerability of infigratinib.
Time Frame: Approximately from baseline to last dose date of study treatment + 30 days, approximately 12 months on average
|
Approximately from baseline to last dose date of study treatment + 30 days, approximately 12 months on average
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Clinical Development, QED Therapeutics
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 27, 2019
Primary Completion (Actual)
March 1, 2023
Study Completion (Actual)
March 1, 2023
Study Registration Dates
First Submitted
December 10, 2018
First Submitted That Met QC Criteria
December 10, 2018
First Posted (Actual)
December 12, 2018
Study Record Updates
Last Update Posted (Actual)
April 3, 2023
Last Update Submitted That Met QC Criteria
March 29, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Cholangiocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
- Infigratinib
Other Study ID Numbers
- QBGJ398-301
- 2018-004004-19 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on FGFR2 Gene Mutation
-
Institut für Klinische Krebsforschung IKF GmbH...Incyte Biosciences International SàrlRecruitingIntrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Gene Translocation | FGFR2 Gene RearrangementGermany
-
Relay Therapeutics, Inc.Active, not recruitingCholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, AdultUnited States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
-
QED Therapeutics, Inc.Helsinn Healthcare SATerminatedFGFR2 Gene Mutation | Advanced CholangiocarcinomaUnited States, Belgium, Germany, Italy, Korea, Republic of, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene AmplificationUnited States, Canada
-
TransThera Sciences (Nanjing), Inc.Active, not recruitingCholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Fusion | FGFR1 Alteration | FGFR3 AlterationUnited States
-
Centre Leon BerardRecruitingCancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditionsFrance, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 and other conditionsUnited States
-
xCuresTerminatedTransitional Cell Carcinoma | Bladder Cancer | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR2 Amplification | Bladder Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Refractory Bladder Carcinoma | Refractory Bladder Urothelial Carcinoma and other conditionsUnited States
-
Taiho Oncology, Inc.Active, not recruitingAdvanced Cholangiocarcinoma | FGFR2 Gene RearrangementsUnited States, Spain, United Kingdom, Australia, Taiwan, Italy, France, Korea, Republic of, Belgium, Japan, Thailand, Germany, Brazil, Peru, Portugal, Argentina, Hong Kong, Mexico, Netherlands, Poland
-
Marc Dall'Era, MDNational Cancer Institute (NCI); Janssen, LPRecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditionsUnited States
Clinical Trials on BGJ398
-
LianBio LLCRecruitingGastric Cancer | Solid Tumor | Gastroesophageal Junction AdenocarcinomaChina
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBladder Cancer | Non-Muscle-Invasive Urothelial CarcinomaUnited States
-
Novartis PharmaceuticalsTerminatedSolid Tumor | Hematologic MalignanciesUnited States
-
Novartis PharmaceuticalsCompletedAdvanced Solid Tumors | Metastatic Solid TumorsFrance, Netherlands, Spain, Canada, Singapore, Germany, Korea, Republic of, Australia, Belgium, Switzerland, Italy, United States
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedRecurrent Glioblastoma or Other Glioma SubtypesSpain, Belgium, United States, Switzerland, Australia, Netherlands
-
QED Therapeutics, Inc.Helsinn Healthcare SATerminatedFGFR2 Gene Mutation | Advanced CholangiocarcinomaUnited States, Belgium, Germany, Italy, Korea, Republic of, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
-
Helsinn Healthcare SALabcorp Drug Development IncWithdrawnAdvanced Solid Tumor | CNS Tumor | Recurrent WHO Grade II GliomaUnited States, Canada, Germany
-
National Institute of Dental and Craniofacial Research...TerminatedOncogenic Osteomalacia | Tumor-Induced OsteomalaciaUnited States
-
University of ChicagoNovartisTerminatedHead and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Human Papillomavirus Infection | Recurrent Oropharyngeal Squamous Cell Carcinoma | FGFR Gene Amplification | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | Recurrent Nasopharynx...United States